TROV TrovaGene Inc.

+0.13  (+3%)
Previous Close 3.86
Open 3.93
Price To Book 1.59
Market Cap 16020672
Shares 4,015,206
Volume 319,638
Short Ratio
Av. Daily Volume 897,022

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 safety and preliminary anti-leukemic activity data to be presented at AACR April 1, 2019; 1pm
Onvansertib (PCM-075)
Acute Myeloid Leukemia (AML)
Phase 1/2 safety and initial efficacy data to be presented at AACR April 2, 2019; 8am.
Onvansertib (PCM-075) and Zytiga
Prostate cancer

Latest News

  1. Trovagene Receives Approximately $3.0 Million From Exercise of Warrants
  2. A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution?
  3. Trovagene Regains Compliance with Nasdaq Listing Requirements
  4. What Should We Expect From TrovaGene, Inc.’s (NASDAQ:TROV) Earnings Over The Next Few Years?
  5. TrovaGene News: Why TROV Stock Is Skyrocketing Today
  6. Trovagene Announces Fourth Quarter and Full-Year 2018 Results
  7. Trovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC at the American Association for Cancer Research Annual Meeting
  8. Trovagene, Inc. Announces Reverse Stock Split
  9. Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference
  10. Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)
  11. Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer
  12. The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen
  13. Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib
  14. New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML
  15. What does TrovaGene Inc’s (NASDAQ:TROV) Balance Sheet Tell Us About Its Future?
  16. Detailed Research: Economic Perspectives on Miller Industries, P & F Industries, Schmitt Industries, Orgenesis, AMERI, and TrovaGene — What Drives Growth in Today's Competitive Landscape
  17. Trovagene, Inc. Receives Positive Nasdaq Listing Decision
  18. Trovagene Announces Launch of New Company Website
  19. Trovagene Announces Third Quarter 2018 Highlights and Financial Results